drugset / Trial / NCT02293460

Efficacy and Safety Study of I10E in Treatment of Patients With CIDP

NCT02293460

Phase 3 Completed 44 enrolled LFB
NaSingle-groupOpen-labelTreatment

Summary

Primary objective: To assess the efficacy of I10E in improving the disability of patients with CIDP. Secondary objective: To assess the safety of I10E in patients with CIDP.

Timeline

Start
2015-05
Primary completion
2017-09-29
Completion
2017-09-29

Drugs

EvaluationDrugModalityDoseRoute
Subject I10E Protein / enzyme biologic 1 g/kg